Soleno Therapeutics, Inc. (SLNO)
| Previous close | 37.34 |
| Open | 37.09 |
| Bid | 38.08 x 200 |
| Ask | 38.40 x 200 |
| Day's range | 37.09 - 38.33 |
| 52-week range | 3.19 - 53.82 |
| Volume | |
| Avg. volume | 312,095 |
| Market cap | 1.277B |
| Beta (5Y monthly) | -1.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 64.33 |
GlobeNewswireSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 96,500 shares of common stock to six employees
GuruFocus.comCEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
GuruFocus.comInsider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
